Cancer

SOPHiA GENETICS Reports Second Quarter 2024 Results

Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss BOSTON and ROLLE, Switzerland,…

2 years ago

VivaWell and Keyzell Holding Announce Strategic Global Cooperation to Develop Innovative AI Health Solutions

MEXICO CITY, MEXICO / ACCESSWIRE / August 6, 2024 / VivaWell, the pioneering healthtech transforming healthcare in Mexico and Argentina,…

2 years ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a…

2 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage…

2 years ago

Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering…

2 years ago

Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders’ Equity Remains Near Record Highs at $36M, or $2.25 per Share

CHICAGO, IL / ACCESSWIRE / August 6, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

2 years ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial…

2 years ago

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results

SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025…

2 years ago

iCAD to Report Second Quarter 2024 Financial Results on August 13, 2024

NASHUA, N.H., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer…

2 years ago